A063: FRS 28: Investment in Associates
Programme Objective
To equip participants with the ability to apply the equity method and to report the investment in associate in accordance with the requirements in FRS 28.
Participants will be able to:
•Understand the definitions in FRS 28, particularly the concept of ‘significant influence’
•Understand the rationale and principles underlying the equity method
•Apply the procedures for accounting for investments in associates in accordance to FRS 28
•Apply the accounting treatment for impairment losses
•Know the disclosure requirements when reporting for investment in associates
Programme Outline
•Scope
•Definitions
◦Significant influence
◦Equity method
◦Other terms
•Identifying an associate
◦Overriding principle
◦Present ownership interests
◦Potential voting rights
◦Other sources of significant influence
•Application of the equity method
◦Exceptions to applying the equity method
◦Applying the substance of consolidation
◦Upstream and downstream transfers
◦Applicability of FRS 103
◦Presentation of the effects of the equity method
◦Accounting policies
◦Non-coterminous reporting dates
◦Discontinuation of the equity method
◦Other considerations
•Impairment losses
◦Applicability of FRS 39
◦Special considerations
•Disclosures
Intended For
A Foundation to Intermediate level programme targeted at both Accounting and Audit Professionals. Those who wish to achieve a deeper understanding in FRS 28 are encouraged to attend.
Competency Mapping
Category 1
Training Methodology
Lecture style, with Exercises/Case Studies
Programme Facilitator(s)
Tan Yee Peng
Yee Peng was a Partner from KPMG LLP in Singapore. Yee Peng was also the Head of KPMG Singapore’s Learning & Development Department and the Professional Practice Department. She is a regular speaker at both in-house and external seminars. She also holds a teaching appointment at NTU.
Yee Peng is a member of ISCA and has a Bachelor of Accountancy, First Class Honours from NTU. She has over 12 years experience in the audits of healthcare, chemicals, semi-conductor, trading, pharmaceuticals and public sector. Her non-audit experience includes: share offerings, financial due diligence for acquisitions, development of costing guidelines, development of financial reporting framework and integration planning.